Small Molecule Hormone or Hormone-Like Ligands of Integrin αVβ3: Implications for Cancer Cell Behavior

Hormones and Cancer

Volumn 4, Issue 6, 2013, Pages 335-342

  Davis, Paul J ^a,b   Mousa, Shaker A ^a   Cody, Vivian ^c   Tang, Heng Yuan ^a   Lin, Hung Yun ^a,d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CISPLATIN; CYCLOOXYGENASE 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; FULVESTRANT; HORMONE RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OSTEOPONTIN; RESVERATROL; THROMBOSPONDIN 1; THYROID HORMONE RECEPTOR; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ACTIN FILAMENT; ALKALINIZATION; ANGIOGENESIS; BINDING SITE; CANCER CELL; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MITOCHONDRIAL RESPIRATION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ESTRADIOL; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INTEGRIN ALPHAVBETA3; LIGANDS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN BINDING; SIGNAL TRANSDUCTION; THYROID HORMONES;

EID: 84887410800     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0156-8     Document Type: Review

References (73)

1. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW (2000) Ligand binding to integrins. J Biol Chem 275: 21785-21788.
2. Campbell ID, Humphries MJ (2011) Integrin structure, activation and interactions. Cold Spring Harb Perspect Biol 3: a004994.
3. Huttenlocher A, Horwitz AR (2011) Integrins in cell migration. Cold Spring Harb Perspect Biol 3(9): a005074.
4. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
5. Somananth PR, Ciocea A, Byzova TV (2009) Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 53: 53-64.
6. Eliceiri BP (2001) Integrin and growth factor receptor crosstalk. Circ Res 89: 1104-1110.
7. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, Davis PJ (2005) Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146: 2864-2871.
8. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY (2011) Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 51: 99-115.
9. Cheng SY, Leonard JL, Davis PJ (2010) Molecular aspects of thyroid hormone actions. Endocr Rev 31: 139-170.
10. Davis PJ, Glinsky GV, Lin HY, Incerpi S, Davis FB, Mousa SA, Tang HY, Hercbergs A, Luidens MK (2013) Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response. Endocr Res 38: 112-118.
11. Farwell AP, Tranter MP, Leonard JL (1995) Thyroxine-dependent regulation of integrin-laminin interactions in astrocytes. Endocrinology 136: 3909-3915.
12. Leonard JL, Farwell AP (1997) Thyroid hormone-regulated actin polymerization in brain. Thyroid 7: 147-151.
13. Hoffman SJ, Vasko-Moser J, Miller WH, Lark MW, Gowen M, Stroup G (2002) Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist. J Pharmacol Exp Ther 302: 205-211.
14. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ (2004) Proangiogeneic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94: 1500-1506.
15. Mousa SA, O'Connor L, Davis FB, Davis PJ (2006) Proangiogenesis action of the thyroid hormone analog 3, 5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin-mediated. Endocrinology 1476: 1602-1607.
16. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ (2005) The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46: 356-360.
17. Cody V, Davis PJ, Davis FB (2007) Molecular modeling of the thyroid hormone interactions with αvβ3 integrin. Steroids 72: 166-170.
18. Lin HY, Cody V, Davis FB, Hercbergs AA, Luidens MK, Mousa SA, Davis PJ (2011) Identification and functions of the plasma membrane receptor for thyroid hormone analogues. Discov Med 11: 337-347.
19. Lin HY, Su Y-F, Hsieh M-T, Lin S, Meng R, London D, Lin C, Tang H-Y, Hwang J, Davis FB, Mousa SA, Davis PJ (2013) Nuclear monomeric integrin αv in cancer cells is a co-activator regulated by thyroid hormone. FASEB J 27: 3209-3216.
20. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ (2009) l-Thyroxine vs. 3, 5, 3′-triiodo-l-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296: C980-C991.
21. Incerpi S, Luly P, De Vito P, Farias RN (1999) Short-term effects of thyroid hormone on the Na/H antiport in l-6 myoblasts: high molecular specificity for 3, 5, 3′-triiodo-l-thyronine. Endocrinology 140: 683-689.
22. D'Arezzo S, Incerpi S, Davis FB, Acconcia F, Marino M, Farias RN, Davis PJ (2004) Rapid nongenomic effects of 3, 5, 3′-triiodo-l-thyronine on the intracellular pH of l-6 myoblasts are mediated by intracellular calcium mobilization and kinase pathways.
23. + exchanger (NHE1) in breast cancer metastasis. Cancer Res 73: 1259-1264.
24. Stock C, Ludwig FT, Schwab A (2012) Is the multifunctional Na(+)/H(+) exchanger isoform 1 a potential therapeutic target in cancer? Curr Med Chem 19: 647-660.
25. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F (2008) Metabolic effects of thyroid hormone derivatives. Thyroid 18: 239-253.
26. Bharali DJ, Yalcin M, Davis PJ, Mousa SA (2013) Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (in press).
27. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ (2008) Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11: 183-190.
28. Safer JD, Crawford TM, Holick MF (2004) Topical thyroid hormone accelerates wound healing in mice. Endocrinology 145: 4425-4430.
29. El-Eter E, Rabee H, Alkayali A, Mousa SA (2007) Role of thyroid hormone analogs in angiogenesis and the development of collaterals in rabbit hind limb ischemia model. J Thromb Thrombolysis 5(suppl 1): 375.
30. Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, Luidens MK, Mousa SA, Hercbergs AH, Davis PJ (2009) Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8: 3554-3562.
31. Meng R, Tang HY, Westfall J, London D, Cao JH, Mousa SA, Luidens M, Hercbergs A, Davis FB, Davis PJ, Lin HY (2011) Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One 6(11): e27547.
32. Mousa SA, Yalcin M, Bharali DJ, Meng R, Tang HY, Lin HY, Davis FB, Davis PJ (2012) Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and in xenografts. Lung Cancer 76: 39-45.
33. Yalcin M, Lin HY, Sudha T, Bharali DJ, Meng R, Tang HY, Davis FB, Stain SC, Davis PJ, Mousa SA (2013) Response of human pancreatic cancer cell xenografts to tetraiodothyroacctic acid nanoparticles. Horm Cancer 4: 176-185.
34. Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, Hercbergs AH, Lin HY, Davis FB, Glinsky GV, Glinskii A, Ma J, Davis PJ, Mousa SA (2010) Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 95: 1972-1980.
35. Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, Mousa SS, Davis FB, Davis PJ, Mousa SA (2010) Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20: 281-286.
36. Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA (2009) Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 29: 3825-3831.
37. Hercbergs A, Davis PJ, Davis FB, Ciesielski MJ, Leith JT (2009) Radiosensitization of GL261 cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8: 2586-2591.
38. Hercbergs A, Lin HY, Davis FB, Davis PJ, Leith JT (2011) Radiosensitization and production of DNA double-strand breaks in U87MG brain tumor cells induced by tetraiodothyroacetic acid (tetrac). Cell Cycle 10: 352-357.
39. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA (2008) Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11: 269-276.
40. Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yan RS, Fu WM (2013) Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol 83: 968-977.
41. Nishio N, Katsura T, Inui K (2008) Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells. Pharm Res 25: 1037-1042.
42. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberian FA, Garcia-Conesa MT, Espin JC (2013) Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 72: 69-82.
43. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
44. Morris BJ (2013) Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med 56: 133-171.
45. Villalba JM, de Cabo R, Alcain FJ (2012) A patent review of sirtuin activators: an update. Expert Opin Ther Pat 22: 355-367.
46. Gehm GD, McAndrews JM, Chien PY, Jameson JL (1997) Resveratrol, a polyphenol compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 94: 14138-14143.
47. Shih A, Davis FB, Lin HY, Davis PJ (2002) Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab 87: 1223-1232.
48. Lin HY, Shih A, Davis FB, Tang HY, Martino LJ, Bennett JA, Davis PJ (2002) Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 168: 748-755.
49. Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY (2004) Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 91: l178-l185.
50. Shih A, Zhang S, Cao HJ, Boswell S, Wu YH, Tang HY, Lennartz MR, Davis FB, Davis PJ, Lin HY (2004) Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol Cancer Ther 3: 1355-1364.
51. Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, Bergh J, Quackenbush S, Davis PJ (2006) Integrin alphavbeta3 contains a receptor site for resveratrol. FASEB J 20: 1742-1744.
52. Hsieh TC, Wong C, John Bennett D, Wu JM (2011) Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin αvβ3. Int J Cancer 129: 2732-2743.
53. Lin HY, Tang HY, Keating T, Wu YH, Shih A, Hammond D, Sun M, Hercbergs A, Davis FB, Davis PJ (2008) Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 29: 62-69.
54. Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate and lung. Inflammopharmacology 17: 55-67.
55. Tang HY, Shih A, Cao HJ, Davis FB, Davis PJ, Lin HY (2006) Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 5: 2034-2042.
56. Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, Davis FB, Davis PJ (2009) Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol 113: 182-188.
57. Levin ER (2009) Plasma membrane estrogen receptors. Trends Endocrinol Metab 20: 477-482.
58. Kelly MJ, Ronnekleiv OK (2012) Membrane-initiated actions of estradiol that regulate reproduction, energy balance and body temperature. Front Neuroendocrinol 33: 376-387.
59. Hammes SR, Levin ER (2011) Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 152: 4489-4495.
60. Dressing GE, Goldberg JE, Charles NJ, Schwertfeger KL, Lange CA (2011) Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids 76: 11-17.
61. Lessey BA (2003) Two pathways of progesterone action in the human endometrium: implications for implantation and contraception. Steroids 68: 809-815.
62. Filla MS, Schwinn MK, Nosie AK, Clark RW, Peters DM (2011) Dexamethasone-associated cross-linked actin network formation in human trabecular meshwork cells involves β3 integrin signaling. Invest Ophthalmol Vis Sci 52: 2952-2959.
63. Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ (2012) Integrin α(v)β3 as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol 14: 500-508.
64. Nakamura I, le Duong T, Rodan SB, Rodan GA (2007) Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25: 337-344.
65. Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X (2006) Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25: 407-413.
66. Mas-Moruno C, Dorfner PM, Manzenrieder F, Neubauer S, Reuning U, Burgkart R, Kessler H (2013) Behavior of primary human osteoblasts on trimmed and sandblasted Ti6A14V surfaces functionalized with integrin αvβ3-selective cyclic RGD peptides. J Biomed Mater Res A 101: 87-97.
67. Mao X, Said R, Louis H, Max JP, Bourhim M, Challande P, Wahl D, Li Z, Regnault V, Lacolley P (2012) Cyclic stretch-induced thrombin generation by rat vascular smooth muscle cells is mediated by the integrin αvβ3 pathway. Cardiovasc Res 96(3): 513-523.
68. Kasirer-Friede A, Kahn ML, Shattil SJ (2007) Platelet integrins and immunoreceptors. Immunol Rev 218: 247264.
69. Mousa SS, Davis FB, Davis PJ, Mousa SA (2010) Human platelet aggregation and degranulation is induced in vitro by l-thyroxine, but not by 3, 5, 3′-triiodo-l-thyronine or diiodothyropropionic acid (DITPA). Clin Appl Thromb Hemost 16: 288-293.
70. Wilder RL (2002) Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61(Suppl 2): ii96-ii99.
71. Laitinen I, Notni J, Phle K, Rudelius M, Farrell E, Nekolla SG, Henriksen G, Neubauer S, Kessler H, Wesler HJ, Schwaiger M (2013) Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction. EJNMMI Res 3(1): 38.
72. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS (2011) Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology 260: 182-191.
73. Freindorf M, Furlani TR, Kong J, Cody V, Davis FB, Davis PJ (2012) Combined QM/MM study of thyroid and steroid hormone analogue interactions with αvβ3 integrin. J Biomed Biotechnol 2012: 959057.